INTRODUCTION
Psoriasis is a common, chronic, inflammatory disease with cutaneous and systemic manifestations that affects approximately 2% of the European population 1 . Given the progression and persistence of the disease, patients diagnosed with psoriasis at a younger age usually need life-long care, implying lifelong expenses. The superiority of secukinumab, reported in two head to head (H2H) clinical trials, provided new horizons to stablish standard of efficacy (clear skin or almost clear skin -PASI 90) for biologic treatments (Bx) for patients with moderate to severe psoriasis 2, 3 . Costs of Bx are on the spot of all Health Care systems. It is key to understand how the superior efficacy of a new treatment can impact on the disease control and Quality of Life (QoL) of patients 4 . Cost per patient achieving disease control (PASI 90) is the most appropriate measure of the real cost of Bx. Otherwise unproven fears on the possible increase of the budget impact for a new Bx might preclude its use.
OBJECTIVE
To compare the cost-efficacy cost of Bx for moderate to severe psoriasis.
METHODS
• We built an average cost-efficacy model represented by a decision tree for a time horizon of 2 years ( Figure 1 ).
• We analyzed all the twenty possible combinations of two consecutive Bx.
Efficacy
• Proportion of patients achieving at least PASI 90 at the end of a time horizon of 2 years.
• Primary failure was considered as patients not achieving at least PASI 75 at week 10-16 (as per Summary of Product Characteristics recommendations) 5 , according experts in Dermatology. These patients were switched to another Bx (consecutive treatment).
• Efficacy was drawn from published clinical trials meta-analysis 5 . For secukinumab and ustekinumab, efficacy data came from CLEAR study (H2H study comparing efficacy of both Bx) 3 .
• Highest efficacy according to meta-analysis (week 24), was assumed constant along the study period 4 .
Costs
• Only pharmacologic costs were included in the analysis. All products were compared using the Spanish Ex-factory Prices in €.
• For secukinumab we used the most expensive price in the market at time of analysis that was the maintenance cost for ustekinumab 45mg. Induction phase costs for the second Bx were ascribed to the first Bx.
Variables for the Analyses
• Number Needed to Treat (NNT) to achieve one patient with at least PASI 90.
• Overall pharmacologic cost along the study period (2 years) • Cost per patient achieving at least PASI 90 Table 1 Shows the order of different treatment strategies, according the number of patients needed to treat to achieve 1 patients with PASI90 in a time horizon of 2 years
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RESULTS
NNT
Cost per patient vs Cost per patient at PASI 90
• Table 2 shows the order of different treatment strategies according the overall cost of two years of treatment, sorted top down from the cheapest to the most expensive. The first Bx is the starting treatment and the second is the BX used to rescue in case of primary failure.
• Table 3 shows the order of those treatment strategies sorted by the cost of achieving one patient in PASI 90 along two years of treatment.
The difference among the cheapest and the most expensive treatment combination is about six thousand euros along two years of treatment. However there is a more than 2-fold difference in efficiency between treatment strategies as evidence by the cost of achieving PASI90. Those treatment combinations with lower NNT (those using secukinumab as first treatment of choice) are the most efficient to achieve patients at PASI 90 in a time period of two years. 
CONCLUSIONS
